|
1
|
Das CJ, Aggarwal A, Singh P, Nayak B, Yadav T, Lal A, Gorsi U, Batra A, Shamim SA, Duara BK, Arulraj K, Kaushal S, Seth A. Imaging Recommendations for Diagnosis, Staging, and Management of Renal Tumors. Indian J Med Paediatr Oncol 2023. [DOI: 10.1055/s-0042-1759718] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/08/2023] Open
Abstract
AbstractRenal cell carcinomas accounts for 2% of all the cancers globally. Most of the renal tumors are detected incidentally. Ultrasound remains the main screening modality to evaluate the renal masses. A multi -phase contrast enhanced computer tomography is must for characterizing the renal lesions. Imaging plays an important role in staging, treatment planning and follow up of renal cancers. In this review , we discuss the imaging guidelines for the management of renal tumors.
Collapse
Affiliation(s)
- Chandan J Das
- Department of Radiodiagnosis and Interventional Radiology, AIIMS, New Delhi, India
| | - Ankita Aggarwal
- Department of Radiodiagnosis, VMMC and SJH, New Delhi, India
| | | | - B Nayak
- Department of Urology, AIIMS, New Delhi, India
| | - Taruna Yadav
- Department of Radiodiagnosis, Jodhpur, Rajasthan, India
| | - Anupam Lal
- Department of Radiodiagnosis, PGI, Chandigarh, India
| | - Ujjwal Gorsi
- Department of Radiodiagnosis, PGI, Chandigarh, India
| | - Atul Batra
- Department of Medical Oncology, AIIMS, IRCH, New Delhi, India
| | | | | | | | | | - Amlesh Seth
- Department of Urology, AIIMS, New Delhi, India
| |
Collapse
|
|
2
|
Percutaneous Image-Guided Cryoablation of Post-Surgical Renal Cancer Recurrences in the Renal Fossa: A Single-Center Retrospective Analysis. Cardiovasc Intervent Radiol 2022; 45:527-529. [PMID: 34977968 DOI: 10.1007/s00270-021-03020-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/14/2021] [Accepted: 09/25/2021] [Indexed: 11/02/2022]
|
|
3
|
Meng H, Yang H, Jia H, Pan F, Dong X, Liu B, Li C. Efficacy and safety of CT-guided microwave ablation for stage T1a renal cell carcinoma in patients with a solitary kidney. Int J Hyperthermia 2021; 38:691-695. [PMID: 33899668 DOI: 10.1080/02656736.2021.1915503] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Abstract
OBJECTIVE To retrospectively evaluate early clinical outcomes of percutaneous microwave ablation (MWA) for stage T1a renal cell carcinomas (RCCs) in solitary kidney patients. MATERIALS AND METHODS 15 solitary kidney patients with 16 stage T1a N0M0 biopsy-proved RCCs underwent CT-guided percutaneous microwave ablation between October 2016 and July 2020. The patients were followed up with contrast-enhanced computed tomography or magnetic resonance imaging at 1, 3, and 6 months and every 6 months thereafter. Serum creatinine levels of each patient pre MWA, 1 day after MWA and the most recent record were collected. Technical effectiveness, local recurrence, survival rates and complications were accessed. RESULTS Complete ablation was achieved in all 16 tumors (100%) including 13 clear cell carcinomas and 3 papillary carcinomas. Within the follow-up time (median: 24 months) no tumor recurrence or major complication was detected. No significant change in serum creatinine level was noted. The cancer-specific survival rate was 100% (15 of 15), and 1-, 2-, and 3-year overall survival rates were 100%, 93.3%, and 93.3%, respectively. CONCLUSION Percutaneous MWA is an effective and safe treatment option for stage T1a RCCs in solitary kidney patients; it can achieve high complete ablation rate in selected lesions of appropriate size and location.
Collapse
Affiliation(s)
- Hong Meng
- Qilu Hospital of Shandong University, Jinan, China
| | - Huan Yang
- Shandong Provincial Hospital affiliated to Shandong First Medical College, Jinan, China
| | - Haipeng Jia
- Qilu Hospital of Shandong University, Jinan, China
| | - Fengmin Pan
- Qilu Hospital of Shandong University, Jinan, China
| | - Xinzhe Dong
- Qilu Hospital of Shandong University, Jinan, China
| | - Bo Liu
- Qilu Hospital of Shandong University, Jinan, China
| | - Chunhai Li
- Qilu Hospital of Shandong University, Jinan, China
| |
Collapse
|
|
4
|
Mauri G, Mistretta FA, Bonomo G, Camisassi N, Conti A, Della Vigna P, Ferro M, Luzzago S, Maiettini D, Musi G, Piacentini N, Varano GM, de Cobelli O, Orsi F. Long-Term Follow-Up Outcomes after Percutaneous US/CT-Guided Radiofrequency Ablation for cT1a-b Renal Masses: Experience from Single High-Volume Referral Center. Cancers (Basel) 2020; 12:cancers12051183. [PMID: 32392792 PMCID: PMC7281086 DOI: 10.3390/cancers12051183] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Revised: 04/24/2020] [Accepted: 05/02/2020] [Indexed: 12/21/2022] Open
Abstract
Image-guided thermal ablations are increasingly applied in the treatment of renal cancers, under the guidance of ultrasound (US) or computed tomography (CT). Sometimes, multiple ablations are needed. The aim of the present study was to evaluate the long-term results in patients with renal mass treated with radiofrequency ablation (RFA) with both US and CT, with a focus on the multiple ablations rate. 149 patients (median age 67 years) underwent RFA from January 2008 to June 2015. Median tumor diameter was 25 mm (IQR 17–32 mm). Median follow-up was 54 months (IQR 44–68). 27 (18.1%) patients received multiple successful ablations, due to incomplete ablation (10 patients), local tumor progression (8 patients), distant tumor progression (4 patients) or multiple tumor foci (5 patients), with a primary and secondary technical efficacy of 100%. Complications occurred in 13 (8.7%) patients (6 grade A, 5 grade C, 2 grade D). 24 patients died during follow-up, all for causes unrelated to renal cancer. In conclusion, thermal ablations with the guidance of US and CT are safe and effective in the treatment of renal tumors in the long-term period, with a low rate of patients requiring multiple treatments over the course of their disease.
Collapse
Affiliation(s)
- Giovanni Mauri
- Division of Interventional Radiology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (G.B.); (N.C.); (P.D.V.); (D.M.); (G.M.V.); (F.O.)
- Department of Oncology and Hematology-Oncology, Università degli Studi di Milano, 20122 Milan, Italy;
- Correspondence:
| | - Francesco Alessandro Mistretta
- Department of Urology, European Institute of Oncology IRCCS, 20141 Milan, Italy; (F.A.M.); (A.C.); (M.F.); (S.L.); (G.M.); (N.P.)
| | - Guido Bonomo
- Division of Interventional Radiology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (G.B.); (N.C.); (P.D.V.); (D.M.); (G.M.V.); (F.O.)
| | - Nicola Camisassi
- Division of Interventional Radiology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (G.B.); (N.C.); (P.D.V.); (D.M.); (G.M.V.); (F.O.)
| | - Andrea Conti
- Department of Urology, European Institute of Oncology IRCCS, 20141 Milan, Italy; (F.A.M.); (A.C.); (M.F.); (S.L.); (G.M.); (N.P.)
| | - Paolo Della Vigna
- Division of Interventional Radiology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (G.B.); (N.C.); (P.D.V.); (D.M.); (G.M.V.); (F.O.)
| | - Matteo Ferro
- Department of Urology, European Institute of Oncology IRCCS, 20141 Milan, Italy; (F.A.M.); (A.C.); (M.F.); (S.L.); (G.M.); (N.P.)
| | - Stefano Luzzago
- Department of Urology, European Institute of Oncology IRCCS, 20141 Milan, Italy; (F.A.M.); (A.C.); (M.F.); (S.L.); (G.M.); (N.P.)
| | - Daniele Maiettini
- Division of Interventional Radiology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (G.B.); (N.C.); (P.D.V.); (D.M.); (G.M.V.); (F.O.)
| | - Gennaro Musi
- Department of Urology, European Institute of Oncology IRCCS, 20141 Milan, Italy; (F.A.M.); (A.C.); (M.F.); (S.L.); (G.M.); (N.P.)
| | - Nicolò Piacentini
- Department of Urology, European Institute of Oncology IRCCS, 20141 Milan, Italy; (F.A.M.); (A.C.); (M.F.); (S.L.); (G.M.); (N.P.)
| | - Gianluca Maria Varano
- Division of Interventional Radiology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (G.B.); (N.C.); (P.D.V.); (D.M.); (G.M.V.); (F.O.)
| | - Ottavio de Cobelli
- Department of Oncology and Hematology-Oncology, Università degli Studi di Milano, 20122 Milan, Italy;
- Department of Urology, European Institute of Oncology IRCCS, 20141 Milan, Italy; (F.A.M.); (A.C.); (M.F.); (S.L.); (G.M.); (N.P.)
| | - Franco Orsi
- Division of Interventional Radiology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (G.B.); (N.C.); (P.D.V.); (D.M.); (G.M.V.); (F.O.)
| |
Collapse
|